

Gilead Sciences Croatia EFPIA Report 2024												
Disclosure date: 30/06/2025												
	Full name (Art. 26.1.)	HCPs: City of Principal Practice HCOs: city where registered (Art. 27.6.)	Country of Principal Practice (Art. 27.6. related to Art. 26.)	Principal Practice Address (Art. 27.6.)	Unique country local identifier (optional) (Art. 23.6.)	Donations to HCOs (Art. 28.1.A.(i))	Contribution to costs of Events (Art. 28.1.A.(ii) and 28.1.B(ii))			Fee for Services (Art. 28.1.A.(iii) and 28.1.B(ii))		TOTAL Optional
							Sponsorship agreements with HCOs/thrid parties appointed by HCOs to manage Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for services contract	
HCPs	INDIVIDUAL NAMED DISCLOSURE – one line per HCP (i.e. all Transfers of Value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultatio only as appropriate)											
	OTHER, NOT INDICATED ABOVE – where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to ToV to such Recipient – Art. 28.2.1.					N/A	N/A					
	Number of Recipients (named list, where appropriate) – Art. 28.2.1.					N/A	N/A		15,533.33 €	4,061.14 €	1,268.61 €	20,863.08 €
	% of the number of Recipients in case of collective publication in relation to the total number of Recipients - Art. 28.2.1.					N/A	N/A		14	3	2	17
HCOs	INDIVIDUAL NAMED DISCLOSURE – one line per HCO (i.e. all Transfers of Value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultatio only as appropriate)											
	OTHER, NOT INDICATED ABOVE – where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to ToV to such Recipient – Art. 28.2.1.											
	Number of Recipients (named list, where appropriate) – Art. 28.2.1.											
	% of the number of Recipients in case of collective publication in relation to the total number of Recipients - Art. 28.2.1.											
R&D	AGGREGATE DISCLOSURE											
	Transfers of Value for Research & Development under Art. 28.2.2.										10,290.99 €	20,863.08 €